Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

A 23-year-old experiencing hair thinning has seen noticeable improvement after using 1.25 mg oral finasteride for over a year and recently starting 2.5 mg oral minoxidil, along with ketoconazole shampoo. They are considering a hair transplant in the future and have not experienced any side effects from the medication.

The user has been using oral finasteride for 15 months and oral minoxidil for 6 months, and developed alopecia areata, for which a dermatologist prescribed calcipotriol/betamethasone. The treatment is helping, but the user is experiencing another shedding phase and is concerned about the effects of the steroid cream and the cause of hair loss.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

The user is 13 months post-hair transplant and is using 1 mg finasteride and 2.5 mg oral minoxidil. They are seeking opinions on their crown's appearance, considering switching treatments, and contemplating a second transplant due to concerns about hair density and stability.

A 21-year-old woman diagnosed with male pattern baldness (MPB) who is considering treatments such as spironolactone, minoxidil and finasteride to address her hair loss. The user also discusses potential solutions for concealing the appearance of her thinning hair, such as wigs or haircuts.

Finasteride may affect liver function and cortisol levels, potentially linking it to non-alcoholic fatty liver disease (NAFLD). More research is needed to understand this connection fully.

The user has been on a comprehensive hair loss treatment regimen for four years, including Dutasteride, topical and oral Minoxidil, and various other treatments, but has seen little progress and is considering a hair transplant. Despite trying multiple therapies, including PRP and exosome injections, the user is still experiencing hair thinning and is hesitant about trying peptides due to potential cancer risks.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

User discusses topical liposomal finasteride for hair loss, hoping to avoid breast growth side effect. Conversation includes using minoxidil, fluridil, and dermarolling, and mentions minimal systemic absorption of liposomal finasteride.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

An 18-year-old has been using minoxidil and finasteride for hair loss since age 15, recently adding dutasteride and GHK-Cu, but sees no significant improvement and is considering a hair transplant. Concerns are raised about using hormone suppressors at a young age, with suggestions to explore other treatments like dermarolling, diet changes, and checking for deficiencies.

The conversation discusses using scalp antiandrogens like RU58841, pyrilutamide, or fluridil on the face to reduce sebum production, noting that clascoterone (winlevi) is an approved facial antiandrogen with underwhelming reviews.

The user is experiencing severe hair loss after surgery and stress, with thinning all over the head, including the sides and neck. They are unsure if it's due to DUPA or alopecia areata incognita, and doctors have not observed miniaturization.

PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

Topical spironolactone is considered safe for males but is not very effective for hair loss. Some users suggest trying it since it's already purchased, while others recommend alternatives like clascoterone.

Glycine may upregulate 5AR, potentially affecting hair. Users suggest using Finasteride to manage hair loss concerns.

The conversation discusses the comparison of Pyrilutamide Phase II US trial results with 1 mg finasteride for hair loss treatment. It mentions that the total hair count increase in the US trial was not as good as the China trial.

The user stopped using finasteride due to side effects and began treatment with Pyrilutamide, while continuing minoxidil, topical melatonin, dermarolling, and Nizoral. They had a second hair transplant to improve their frontal hairline and will report back on the results of the new treatment regimen.

The user is experiencing reduced hair shedding and increased hair density after using finasteride, minoxidil, derma rolling, granactive retinoid, and Nizoral, while also taking testosterone and aromatase inhibitors. They question if they are a hyper responder to the treatments, despite mixed feedback from others about visible progress.

A 26-year-old man who had a hair transplant and used minoxidil with good results is now experiencing shedding and considering finasteride. He's concerned about high progesterone and mild erectile dysfunction before starting the treatment.

A 21-year-old has been using 0.4mg finasteride and 1mg oral minoxidil (increased to 2mg) for 9 months with no noticeable hair growth and worsening hair condition. They are considering stopping finasteride due to side effects and are seeking advice on other treatments.

A 24-year-old woman being diagnosed with androgenic alopecia (AGA) who is scared and confused about her hair loss, and the treatment options of Minoxidil, finasteride, RU58841, spironolactone, and possibly a biopsy.

Male pattern baldness (MPB) may be influenced by androgen receptors in scalp hair follicles and potentially poor blood flow. Transplanted hair is not immune to DHT, and factors like inflammation and scalp tension might also contribute to hair loss.

Hair loss can be treated by correcting glucose metabolism in hair follicles and using equol as a safer DHT blocker. Production of these treatments is starting soon, and a Discord channel is available for more information.

Spudlady asks about experiences with spironolactone for hair loss. She has lost hair due to stress and seeks ways to stop shedding.

Eli Lilly's drug baricitinib showed effectiveness in treating alopecia areata, with higher doses resulting in significant hair regrowth compared to placebo. The treatment is not for male pattern baldness.

PP405 and hair cloning are discussed as potential treatments for reversing hair loss from Norwood 7 to Norwood 1. Hair cloning is seen as a more permanent solution, while PP405's effectiveness and long-term effects remain uncertain.

The conversation discusses using Botox to treat male pattern baldness, suggesting it may promote hair growth by increasing scalp blood flow and oxygen, reducing dihydrotestosterone levels. The user wonders why this treatment is not widely discussed or if it has been discredited.